Waldencast plc, through its Obagi Medical division, announced a collaboration with DermFx as part of the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program. The initiative aims to generate real-world evidence for the injectable product Obagi® saypha® MagIQ™. DermFx providers will participate in structured evaluation programs across multiple locations to assess the safety, efficacy, and patient satisfaction associated with the product, building on data from previous FDA pivotal trials. Initial findings from the program will be presented at upcoming internal team meetings and regional events.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Waldencast plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9650083) on February 06, 2026, and is solely responsible for the information contained therein.